Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Seagate Technology Holdings PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Seagate Technology Holdings PLC trades at $871.38 (market cap $205.97B). The key difference: Seagate Technology Holdings PLC is far larger — about 5.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Seagate Technology Holdings PLC pays a 0.33% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | STX | |
|---|---|---|
Market Cap | $39.89B | $205.97B |
Sector | Health | Technology |
52-Week High | $491.22 | $1.09K |
52-Week Low | $278.09 | $146.59 |
Enterprise Value | $38.15B | $209.00B |
Dividend Yield | — | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Seagate Technology (STX) trades at $910.34, up 2.28% with strong momentum driven by AI infrastructure demand. The stock shows impressive fundamental improvement with revenue growth from $6.6B to $9.1B and net income surging to $1.47B in 2025. Technical indicators are mixed with bullish moving averages but neutral oscillators, while analyst sentiment remains positive with a $981.43 consensus target representing 7.8% upside potential.
STX presents compelling growth prospects as AI-driven storage demand accelerates, supported by three consecutive earnings beats and expanding margins. Key risks include high valuation multiples (P/E 86.37), significant debt levels, and competitive pressures in the storage market. The company's positioning in AI infrastructure and strong institutional support suggest continued upside potential despite elevated valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
